Figure 4 | International Journal of Obesity

Figure 4

From: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

Figure 4

(a) The prevalence of prediabetes and the metabolic syndrome at randomization and after 1 and 2 years of treatment. Metabolic syndrome is defined by updated NCEP-ATP III criteria.16 (b) Mean changes in lipids from randomization to years 1 and 2. Estimated (ANCOVA) changes are shown for the intention-to-treat population with the last observation carried forward.

Back to article page